Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anatomic Stage III Breast Cancer AJCC v8 clinical trials
48 of 85 indexed Anatomic Stage III Breast Cancer AJCC v8 trials are currently recruiting.
85 US clinical trials · 48 currently recruiting
Anatomic Stage III Breast Cancer AJCC v8 is the subject of 85 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 14 of these trials.
The research picture
Anatomic Stage III Breast Cancer AJCC v8 has 85 registered US clinical trials, 48 of them open to new participants right now, about 56% of the total.
- 48
- recruiting participants now
- 56%
- of trials open to enrollment
- 8
- in Phase 3–4 (later-stage)
- 14
- top sponsor: National Cancer Institute (NCI)
Active & Recent Trials
85 total, page 2 of 2
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01334021
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
NCT04457596
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
NCT02115282
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
SWOG Cancer Research Network
NCT05568472
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Alliance for Clinical Trials in Oncology
NCT04549571
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT04906200
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
Thomas Jefferson University
NCT04086875
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
M.D. Anderson Cancer Center
NCT04754412
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
ECOG-ACRIN Cancer Research Group
NCT04001829
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
ECOG-ACRIN Cancer Research Group
NCT05710328
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
Mayo Clinic
NCT04443413
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT05049746
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
NCT02849496
Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT03786354
A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors
University of Washington
NCT06392789
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02453620
Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial
Fred Hutchinson Cancer Center
NCT06643455
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
University of Washington
NCT05455658
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
NCT06630325
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
M.D. Anderson Cancer Center
NCT05025059
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
NCT04345913
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03218826
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT04673448
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
NCT03179904
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
NCT03941730
Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer
M.D. Anderson Cancer Center
NCT00507923
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
NCT04862585
An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT05012176
An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information
Fred Hutchinson Cancer Center
NCT06193070
Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT03505671
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
M.D. Anderson Cancer Center
NCT03620201
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
NCT03207529
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
NCT03774472
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT04205903
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 23 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Anatomic Stage III Breast Cancer AJCC v8 Trial Landscape
85 indexed Anatomic Stage III Breast Cancer AJCC v8 studies · 48 recruiting (56%).
Phase mix: 8 late (III/IV) vs 43 early (I/II).
Top sponsor: National Cancer Institute (NCI) (14 trials), 9 others listed. 35 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Anatomic Stage III Breast Cancer AJCC v8?
PlainTrial tracks 85 US clinical trials for Anatomic Stage III Breast Cancer AJCC v8, of which 48 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Anatomic Stage III Breast Cancer AJCC v8?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.